Brief: Lundbeck, Otsuka get positive opinion for schizophrenia drug
20/09/2013 12:15
COPENHAGEN, Sept 20 (Reuters) - Danish pharmaceutical group H. Lundbeck A/S LUN.CO said on Friday: * It and Japanese partner Otsuka Pharmaceutical Co., Ltd. ,4768.T> have receive positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) * Committee recommends marketing authorisation for Abilify Maintena (aripiprazole), a treatment for the maintenance of schizophrenia ((Copenhagen newsroom, tel: +45 33969649, e-mail: copenhagen.newsroom@thomsonreuters.com)) ((For more news, double-click on LUN.CO [4768.T))